For the study, participants either received 10mg of escitalopram daily for seven days followed by 20mg daily for the next seven days, including the day of psilocybin administration, or 14 days of placebo pre-treatment before psilocybin administration. The researchers found that pre-treatment with escitalopram did not alter the pharmacokinetics of psilocin — the active compound that the…
…successfully obtained government approvals for a doctor to prescribe… to patients to take… unsupervised in the community… …data collected from 80 participants from over the course of 12 months and 1,102 microdoses. The daily questionnaire showed credible evidence of increased ratings from participants in energy, wellness, creativity, happiness and connectedness on the dose days… the…
Despite the seriousness of those findings, acetaminophen nonetheless remains one of the most used medications in the world, considered an essential medicine by the World Health Organization, and recommended by the CDC for pain relief at home… the findings are reported in Social Cognitive and Affective Neuroscience. “Acetaminophen seems to make people feel less negative emotion when they…
In order to have physical dependence your body needs to start relying on a substance to function properly. …there does not appear to be any sort of physiological mechanism that would make your body “dependent” on psilocin in such a way that you’d experience physical effects from stopping a regimen. In other words, no, you’re…
Among 3813 PWUD at baseline, 1093 (29%) reported daily use of illicit opioids and 229 (6%) reported psychedelic use in the past six months. Over study follow-up after adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use (Adjusted Odds Ratio: 0.45; 95%…
This examination of a large international sample of adults highlights the prominence of therapeutic and wellness motivations for microdosing psychedelic drugs and identified lower levels of anxiety and depression among microdosers relative to controls. Comparisons of psilocybin to LSD microdosers indicated no differences on measures of Depression, Anxiety and Stress from the DASS-21 (all values for F (1, 827) < 1.0, p > 0.50). The inclusion of…
Researchers at Imperial College London [report]… Use of cannabis together with psychedelics was “associated with higher scores of mystical-type experience, ego-dissolution and visual alterations,” the study, published last week in the journal Psychopharmacology, states. And in general, the more marijuana a person said they used, the more intense the psychedelic effect… there was a unique…
…[ie] deuterated psilocybin analog has a duration of effect that is half is long as psilocybin, and a duration onset that is twice as fast. …[research pipeline seeking & developing] drugs with less variability [with goals such as] a faster onset time and better brain penetration that maintain the therapeutic properties of psilocybin and deliver…
…a 35-percent response rate and a 5-percent SAE rate means for every seven patients positively responding to the treatment, one person will experience serious negative outcomes… these serious adverse events included suicidal ideation and suicidal behavior. Five patients (6.3 percent) in the 25-mg group and six patients (8 percent) in the 10-mg group experienced at…
With… propriety technology… stable formulations of both psilocin and psilocybin from magic mushrooms. …drug development efforts are focused exclusively on extracting, purifying, and standardizing natural psychedelic compounds. Original Article (Psychedelic Spotlight):FDA approves first clinical trial using naturally sourced psychedelicsArtwork Fair Use: Perdula
Recent Comments